Shots:
Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging.
Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited
Raphaël…
Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience.
Konrad believes…
Vikram Mohan will be joining the upcoming Pharma 2025 event as a panelist with the Topic “Content’s Industrial Revolution”. Vikram believes that with a paradigm shift from the traditional approach to creating, approving, reviewing, and deploying content in the evolving biopharma industry, there’s room for generative AI to act as an assistant to make the…
Shots:
GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis
The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions.
In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…
Shots:
Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024
At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief …
Shots:
Smile Train is a proud partner of the FDI World Dental Federation's annual World Oral Health Day Campaign, which is focusing this year on the theme "A Happy Mouth is a Happy Mind" to promote the importance of oral health and mental health
Through this campaign, Smile Train's goal is to educate the world…
Shots:
Developments in healthcare technologies are setting new standards at present and encouraging exploration into emerging technologies to advance care and enhance the lives of patients globally
Digital Twins are virtual replicas of objects, individuals, or systems spanning their life cycles
The article introduces the role of digital twins in the healthcare system, the advantages,…
Shots:
At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P
The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P
Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
With breakthrough discoveries addressing patients' unmet needs, caregivers, decision-makers, and advocacy groups have made great strides towards bringing patient experience to the mainstream.
Today's guest is TJ Sharpe, a Patient Insights Expert and Stage-IV Melanoma survivor. In his topic "Complicating is easy, Simplifying is Difficult, the personalized patient experience", T.J. will shed light on patient…

